drug

argatroban

Marketedupdated 2mo ago

by Mylan Institutional Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 26, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

Sep 26, 2027formulationUS 75891061.2y
Sep 26, 2027formulationUS 76875161.2y

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying argatroban

phase2Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)completedn=140
phase2Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type IIcompletedn=20
phase4Safety of Argatroban Infusion in Conduction Disturbancescompletedn=50